

*Unless defined herein, terms used in this announcement shall have the same meanings as those defined in the prospectus dated 25 June 2015 (the “**Prospectus**”) issued by PuraPharm Corporation Limited (the “**Company**”).*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Shares being offered.

*This announcement is not an offer of securities for sale in the United States. The Company has not registered and does not intend to register any securities referred to in this announcement under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”). Securities of the Company may not be offered or sold in the United States absent registration under the U.S. Securities Act or an applicable exemption from the registration requirements under the U.S. Securities Act. There will not be and is not currently intended to be any public offering of securities in the United States.*

*In connection with the Global Offering, BOCOM International Securities Limited, as the stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules, as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).*

Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on Thursday, 30 July 2015, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, and demand for the Shares and the price of the Shares could fall.



PuraPharm

PuraPharm Corporation Limited

培力控股有限公司

(incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering : 71,130,000 Shares (comprising 56,250,000 new Shares and 14,880,000 Sale Shares) (subject to adjustment and the Over-allotment Option)

Number of Hong Kong Public Offer Shares : 7,113,000 Shares (subject to adjustment)

Number of International Offer Shares : 64,017,000 Shares (comprising 49,137,000 new Shares and 14,880,000 Sale Shares) (subject to adjustment and the Over-allotment Option)

Maximum Offer Price : HK\$6.19 per Offer Share (payable in full on application, plus a brokerage of 1.0%, an SFC transaction levy of 0.0027% and a Stock Exchange trading fee of 0.005% and subject to refund) and expected to be not less than HK\$5.16 per Offer Share

Nominal value : US\$0.10 per Share

Stock code : 1498

Sole Sponsor, Sole Global Coordinator and Sole Bookrunner



Joint Lead Managers



Application has been made by the Company to the Listing Committee for the listing of, and permission to deal in, the Shares in issue and to be issued pursuant to the Global Offering and the Capitalisation Issue (including any additional Shares which may be issued pursuant to the exercise of the Over-allotment Option and the exercise of any option which have been or may be granted under the Share Option Scheme). The Global Offering comprises (a) the Hong Kong Public Offering of 7,113,000 Shares (subject to adjustment) and (b) the International Offering of 64,017,000 Shares (comprising 49,137,000 new Shares and 14,880,000 Sale Shares) (subject to adjustment and the Over-allotment Option), representing approximately 10% and approximately 90%, respectively of the Offer Shares under the Global Offering (without taking into account the exercise of the Over-allotment Option).

Subject to the granting of the approval for the listing of, and permission to deal in, the Shares on the Hong Kong Stock Exchange and compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the Shares on the Hong Kong Stock Exchange or such other date as may be determined by HKSCC. Settlement of transactions between participants of the Hong Kong Stock Exchange is required to take place in CCASS on the second Business Day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the Shares to be admitted into CCASS.

In connection with the International Offering, the Company is expected to grant the Over-allotment Option to the International Underwriter, exercisable by the Sole Global Coordinator at its sole and absolute discretion on behalf of the International Underwriters for up to 30 days after the last day for the lodging of applications under the Hong Kong Public Offering. Pursuant to the Over-allotment Option, the Sole Global Coordinator will have the right to require the Company to issue and allot up to an aggregate of 10,669,500 Shares, representing 15% of the initial number of the Offer Shares, at the Offer Price to cover over-allocations in the International Offering, if any. The allocation of the Shares between the Hong Kong Public Offering and the International Offering is subject to adjustment as stated in the section headed “Structure of the Global Offering — The Hong Kong Public Offering — Reallocation” in the Prospectus.

Assuming the Global Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Wednesday, 8 July 2015, it is expected that dealings in the Shares on the Hong Kong Stock Exchange will commence at 9:00 a.m. on Wednesday, 8 July 2015. In the event that the Over-allotment Option is exercised, an announcement will be made by the Company on the websites of the Hong Kong Stock Exchange and the Company at www.hkexnews.hk and at www.purapharm.com, respectively.

The Offer Price will not be more than HK\$6.19 per Offer Share and is expected to be not less than HK\$5.16 per Offer Share. Applicants for the Hong Kong Public Offer Shares are required to pay, on application, the maximum Offer Price of HK\$6.19 per Offer Share together with a brokerage of 1.0%, an SFC transaction levy of 0.0027% and a Hong Kong Stock Exchange trading fee of 0.005%, subject to refund if the Offer Price as finally determined is less than HK\$6.19 per Offer Share.

Applications for the Hong Kong Public Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, the Application Forms and the designated website (www.eipo.com.hk) for the White Form eIPO.

Applicants who would like to have the Hong Kong Public Offer Shares to be allotted and issued in their own names should:

- (i) complete and sign the **WHITE** Application Forms; or
- (ii) submit applications online through the designated website of the **White Form eIPO** Service Provider at www.eipo.com.hk under the **White Form eIPO** service.

Applicants who would like to have the Hong Kong Public Offer Shares to be allotted and issued in the name of HKSCC Nominees Limited and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants maintained in CCASS should either:

- (i) complete and sign the **YELLOW** Application Forms; or
- (ii) give **electronic application instructions** to HKSCC via CCASS.

Copies of the Prospectus, together with the **WHITE** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Thursday, 25 June 2015 until 12:00 noon on Tuesday, 30 June 2015 from:

- (1) any of the following addresses of the Hong Kong Underwriters:

BOCOM International Securities Limited	9th Floor, Man Yee Building 68 Des Voeux Road Central Hong Kong
---	---

DBS Asia Capital Limited	17th Floor, The Center 99 Queen's Road Central Hong Kong
---------------------------------	--

RHB OSK Securities Hong Kong Limited 12/F World-Wide House
19 Des Voeux Road Central
Hong Kong

Bright Smart Securities International (H.K.) Limited 10/F, Wing On House
71 Des Voeux Road Central
Hong Kong

(2) any of the following branches of the following receiving banks:

(a) **Bank of Communications Co., Ltd. Hong Kong Branch**

	Branch Name	Address
Hong Kong Island	Hong Kong Branch Kennedy Town Sub-Branch	20 Pedder Street, Central G/F., 113-119 Belcher's Street, Kennedy Town
Kowloon	Tsim Sha Tsui Sub-Branch Lam Tin Sub-Branch	Shop 1-3, G/F., 22-28 Mody Road, Tsim Sha Tsui Shop No. 5 & 9, G/F., Kai Tin Tower, 63-65 Kai Tin Road, Lam Tin
New Territories	Tiu Keng Leng Sub-Branch Fanling Sub-Branch	Unit L2-064 & 065, Metro Town Shopping Mall, 8 King Ling Road, Tiu Keng Leng Shop No. 84A-84B, G/F., Flora Plaza, Fanling

(b) **DBS Bank (Hong Kong) Limited**

	Branch Name	Address
Hong Kong Island	North Point Branch Hennessy Road Branch Aberdeen Branch	G/F, 391 King's Road, North Point G/F, 427-429 Hennessy Road, Causeway Bay Shops A & B, G/F, Units A & B, 1/F, On Tai Building, 1-3 Wu Nam Street, Aberdeen

	Branch Name	Address
Kowloon	Hoi Yuen Road Branch	Unit 2, G/F, Hewlett Centre, 54 Hoi Yuen Road, Kwun Tong
	Yaumatei Branch	G/F & 1/F, 131-137 Woo Sung Street, Yau Ma Tei
New Territories	Ma On Shan Branch	Shop 205-206, Level 2, Ma On Shan Plaza, Ma On Shan
	Shatin Plaza Branch	Shop 47 & 48, Level 1, Shatin Plaza, No. 21-27 Sha Tin Centre Street, Shatin

Copies of the Prospectus, together with the **YELLOW** Application Form, may be obtained during normal business hours from 9:00 a.m. on Thursday, 25 June 2015 until 12:00 noon on Tuesday, 30 June 2015 at the **Depository Counter of HKSCC** at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong or your stockbroker, who may have such Application Forms and the Prospectus available.

Your **WHITE** or **YELLOW** Application Form completed in accordance with the instructions printed thereon, together with a cheque or a banker's cashier order attached and marked payable to "Bank of Communications (Nominee) Co. Ltd. — PuraPharm Public Offer" for the payment, should be deposited in the special collection boxes provided at any of the designated branches of the receiving banks listed above, at the following times:

Thursday, 25 June 2015 — 9:00 a.m. to 5:00 p.m.

Friday, 26 June 2015 — 9:00 a.m. to 5:00 p.m.

Saturday, 27 June 2015 — 9:00 a.m. to 1:00 p.m.

Monday, 29 June 2015 — 9:00 a.m. to 5:00 p.m.

Tuesday, 30 June 2015 — 9:00 a.m. to 12:00 noon

Applicants applying by **White Form eIPO** service may submit applications through the designated website at **www.eipo.com.hk** from 9:00 a.m. on Thursday, 25 June 2015 until 11:30 a.m. on Tuesday, 30 June 2015 (24 hours daily, except on the last application day) or such later time as described in the section headed "*How to Apply for Hong Kong Public Offer Shares — Effect of Bad Weather on the Opening of the Application Lists*" in the Prospectus.

CCASS Participants can input **electronic application instructions** from 9:00 a.m. on Thursday, 25 June 2015 until 12:00 noon on Tuesday, 30 June 2015 or such later time as described in the section headed “*How to Apply for Hong Kong Public Offer Shares — Effect of Bad Weather on the Opening of the Application Lists*” in the Prospectus.

Please refer to the sections headed “*Structure of the Global Offering*” and “*How to Apply for Hong Kong Public Offer Shares*” in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

The Company expects to publish an announcement on the final Offer Price, the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Public Offer Shares on Tuesday, 7 July 2015 on the websites of the Hong Kong Stock Exchange and the Company at **www.hkexnews.hk** and at **www.purapharm.com**, respectively. The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering will be made available through a variety of channels from Tuesday, 7 July 2015 as described in the section headed “*How to Apply for Hong Kong Public Offer Shares — Publication of Results*” in the Prospectus.

No temporary documents of title will be issued in respect of the Shares and no receipt will be issued for sums paid on application. Share certificates will only become valid certificates of title at 8:00 a.m. on Wednesday, 8 July 2015 provided that the Global Offering has become unconditional in all respects and the right of termination described in the section headed “*Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination*” has not been exercised.

Dealings in the Shares on the Hong Kong Stock Exchange are expected to commence at 9:00 a.m. on Wednesday, 8 July 2015. The Shares will be traded in board lots of 500 Shares each and the stock code of the Company is 1498.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong
25 June 2015

As at the date of this announcement, the executive directors of the Company are Chan Yu Ling, Abraham, Tsoi Kam Biu, Alvin, Leung Chin Man and Man Yee Wai, Viola; the non-executive director of the Company is Chan Kin Man, Eddie; and the independent non-executive directors of the Company are Leung Lim Kin, Simon, Chan Kin Keung, Eugene, Ho Kwok Wah, George and Tsui Lap Chee.